2026-04-29T06:16:12Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/180692024-11-28T14:50:07Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Padilla-Galo, A.
author
Levy-Abitbol, RCh.
author
Olveira, C.
author
Valencia Azcona, B.
author
Pérez Morales, M.
author
Rivas-Ruiz, F.
author
Tortajada-Goitia, B.
author
Moya-Carmona, I.
author
Levy-Naon, A.
authoraffiliation
[Padilla-Galo,A; Valencia Azcona,B; Pérez Morales,M] Pneumology Unit. Agencia Sanitaria Costa del Sol. Marbella, Málaga, Spain. [Levy-Abitbol,RCh] Yeshiva University, New York, USA. [Olveira,C] Pneumology Department, IBIMA (Institute for Biomedical Research of Málaga), Regional University Hospital of Málaga/ University of Málaga, Málaga, Spain. [Olveira,C] Málaga, Spain. [Rivas-Ruiz,F] Research Unit, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, REDISSEC (Spanish healthcare network for chronic diseases), Agencia Sanitaria Costa del Sol. Marbella, Málaga, Spain. [Tortajada-Goitia,B] Pharmacy and Nutrition Service, Agencia Sanitaria Costa del Sol. Marbella, Málaga, Spain. [Moya-Carmona,I] Pharmacy and Nutrition Service, Hospital Universitario Virgen de la Victoria, Málaga, Spain [Levy-Naon,A] Pneumology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
2024-02-12T19:46:35Z
2024-02-12T19:46:35Z
2020-06-29
http://hdl.handle.net/10668/4284
http://hdl.handle.net/20.500.12105/18069
32600318
10.1186/s12890-020-01220-9
1471-2466
BMC Pulmonary Medicine
Background: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients. Methods: This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units. Results: A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7, p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7, p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75], p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0], p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroiddependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline(64.4 ± 9.3 vs 73.1 ± 9.1, p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12, p = 0.002). Side effects were mild and did not lead to treatment discontinuation. Conclusions: This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.
eng
Asthma
Benralizumab
Eosinophils
Biologics
Severe asthma
Eosinophilic asthma
Real-life
Asma
Eosinófilos
Productos biológicos
Andalucía
Real-life experience with benralizumab during 6 months
research article